CN110496121A - Dihydroqinghaosu resists the application in leishmanial drug in preparation - Google Patents
Dihydroqinghaosu resists the application in leishmanial drug in preparation Download PDFInfo
- Publication number
- CN110496121A CN110496121A CN201910785568.1A CN201910785568A CN110496121A CN 110496121 A CN110496121 A CN 110496121A CN 201910785568 A CN201910785568 A CN 201910785568A CN 110496121 A CN110496121 A CN 110496121A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- nmr
- cdcl
- independently
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 title claims abstract description 15
- 229960002521 artenimol Drugs 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- -1 amino, hydroxyl Chemical group 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 241000222727 Leishmania donovani Species 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 6
- 241000222722 Leishmania <genus> Species 0.000 claims description 5
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000001924 fatty-acyl group Chemical group 0.000 claims 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 190
- 238000005160 1H NMR spectroscopy Methods 0.000 description 50
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 45
- 238000004896 high resolution mass spectrometry Methods 0.000 description 42
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000002002 slurry Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 229930101531 artemisinin Natural products 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 229930183339 qinghaosu Natural products 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 2
- 206010011668 Cutaneous leishmaniasis Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- JAAIPIWKKXCNOC-UHFFFAOYSA-N 1h-tetrazol-1-ium-5-thiolate Chemical compound SC1=NN=NN1 JAAIPIWKKXCNOC-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- ZPOLNCDBPYJDSE-UHFFFAOYSA-N 3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid Chemical compound O=CNC(C(=O)O)CC1=CC=C(N(CCCl)CCCl)C=C1 ZPOLNCDBPYJDSE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- WZUUZPAYWFIBDF-UHFFFAOYSA-N 5-amino-1,2-dihydro-1,2,4-triazole-3-thione Chemical compound NC1=NNC(S)=N1 WZUUZPAYWFIBDF-UHFFFAOYSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N 5-methyl-2h-tetrazole Chemical compound CC=1N=NNN=1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical compound C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241000282858 Hyracoidea Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000222714 Trypanosomatidae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N carbostyril Natural products C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses dihydroqinghaosus shown in Formulas I to resist the application in leishmanial drug in preparation, has widened the pharmaceutical applications of dihydroqinghaosu.
Description
Technical field
The invention belongs to the medical usage technical fields of compound, are related to a kind of dihydroqinghaosu and are preparing anti-benefit
Application in the drug of assorted graceful protozoon.
Background technique
Qinghaosu and its derivative have efficient, quick and less toxic antimalarial active, obtain in worldwide extensively
Using.Recent study, which shows qinghaosu and its derivative also, to be had anti-inflammatory, antibacterium pyemia, anti-tissue fibrosis and resists
The multiple biological activities such as tumour.At present to the research of qinghaosu be concentrated mainly on raising activity, widen drug effect, increase stability and
Dissolubility etc..Some active small moleculars or drug are introduced into dihydro in past research by seminar where inventor
In qinghaosu structure, the dihydroqinghaosu of various structures type is devised, by the exploration of condition, simple, high yield
Ground realizes the synthesis of these target compounds, although and find that part of compound itself does not have antibacterial action, its
It can be used as the Trimethoprim of beta-lactam antibiotic.
Leishmania (Leishmania spp.) refers to the Trypanosomatidae protozoon of Leishmania, is that a kind of can cause
The helminth of leishmaniasis.Leishmanial main host is vertebrate, and common infection object includes Hyracoidea, grinding tooth
Mesh, Canidae and the mankind.There are three types of principal modes for leishmaniasis: visceral (most serious), Cutaneous (most common) and mucocutaneous
Property.Wherein visceral leishmaniasis is also referred to as kala-azar, is caused by Leishmania donovani (Leishmania donovani),
It is characterized in that fever, weight loss, spleen and liver enlargement and the irregular breaking-out of anaemia, are frequently-occurring in the Indian subcontinent and East Africa
Endemic disease, if without treatment, be more than 95% case in be lethal.Cutaneous Leishmaniasis is visceral leishmaniasis
Sequelae, usually obviously cure kala-azar after 6 months to 1 year or for many years occur, it is also possible to occur earlier, lead to
Often cause cutaneous lesions, mainly ulcer in the exposure portion of body, leaves lifelong scar and serious deformity, it is main to occur
In East Africa and the Indian subcontinent, the people with cutaneous Leishmaniasis is considered as the potential kala-azar source of infection.Li Shiman at present
There are safety/toxicity problem (including cardiac toxic), cure rates for the treatment of disease not exclusively, application is difficult, duration for the treatment of
Length lacks compliance and develops drug resistance.
Summary of the invention
It is an object of the invention to investigate activity of the dihydroqinghaosu in terms of anti-Leishmania, to widen two
The pharmaceutical applications of hydrogen arteannuin derivative.
Through studying, the invention provides the following technical scheme:
Dihydroqinghaosu shown in Formulas I or its raceme, stereoisomer, tautomer, nitrogen oxides, medicine
Acceptable salt resists the application in leishmanial drug in preparation on:
In Formulas I, n is 1 or 2；
Y is-NR1R2、
R1And R2It independently is H, C1-C3 alkyl or C1-C3 hydroxyalkyl；
R3For H, C1-C3 alkyl, C1-C3 hydroxyalkyl, phenyl substituted or unsubstituted, tertbutyloxycarbonyl, benzyloxycarbonyl group or rouge
Fat acyl group；Substituent group on the phenyl is one or more, is independently selected from halogen, hydroxyl, amino or C1-C3 alkyl；
R4And R5It independently is H or C1-C3 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C3 alkyl；
R8For H, C1-C3 alkyl, C1-C3 alkylthio group, phenyl substituted or unsubstituted；Substituent group on the phenyl is one
Or it is multiple, it is independently selected from halogen, hydroxyl, amino or C1-C3 alkyl.
Further, in Formulas I,
R1And R2It independently is H, C1-C2 alkyl or C1-C2 hydroxyalkyl；
R3For H, C1-C2 alkyl, C1-C2 hydroxyalkyl, phenyl substituted or unsubstituted, tertbutyloxycarbonyl, benzyloxycarbonyl group or alkane
Acyl group；Substituent group on the phenyl is one or more, is independently selected from halogen, hydroxyl, amino or C1-C2 alkyl；
R4And R5It independently is H or C1-C2 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C2 alkyl；
R8For H, C1-C2 alkyl, C1-C2 alkylthio group, phenyl substituted or unsubstituted；Substituent group on the phenyl is one
Or it is multiple, it is independently selected from halogen, hydroxyl, amino or C1-C2 alkyl.
Further, in Formulas I,
R1And R2It independently is H, C1-C2 alkyl or C1-C2 hydroxyalkyl；
R3For H, C1-C2 alkyl, C1-C2 hydroxyalkyl, phenyl, tertbutyloxycarbonyl, benzyloxycarbonyl group or acetyl group；
R4And R5It independently is H or C1-C2 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C2 alkyl；
R8For H, C1-C2 alkyl, C1-C2 alkylthio group or phenyl.
Further, in Formulas I,
R1And R2It independently is H, methyl, ethyl or ethoxy；
R3For H, methyl, ethoxy, phenyl or tertbutyloxycarbonyl；
R4And R5It independently is H or methyl；
R6And R7It independently is H or amino；
R8For H, methyl, methyl mercapto or phenyl.
Further, dihydroqinghaosu shown in Formulas I is any one of following compound:
Further, dihydroqinghaosu shown in Formulas I is any one of following compound: 1h, 2a-4,2a-5,
3a-6,3b-5,3b-6,4a-5,4a-7,4b-6,4b-7,4b-8,5a-2,5a-4,5a-5,5b-2,5b-5。
Further, the Leishmania is Leishmania donovani (Leishmania donovani).
Unless otherwise stated, the term " raceme " in the present invention refers to that the optics being made of equal parts of enantiomers is not active
Organic matter." stereoisomer " refers to atom composition and molecule bonded identical and that atom is different on three-dimensional arrangement." mutually
Tautomeric " refers to the functional isomer because atom a certain in molecule generates due to two positions are moved rapidly." nitrogen oxidation
Object " refers to that three-level nitrogen connection oxygen atom is formed+N-O-The organic matter of structural unit." pharmaceutically acceptable salt " can be acidity
Salt is also possible to basic salt, such as inorganic acid salt, acylate, inorganic base salts or organic alkali salt.
The beneficial effects of the present invention are: the invention discloses dihydroqinghaosus shown in Formulas I to prepare anti-benefit
Application in the drug of assorted graceful protozoon, has widened the pharmaceutical applications of dihydroqinghaosu.
Specific embodiment
It, below will be to preferred reality of the invention in order to keep the purpose of the present invention, technical scheme and beneficial effects clearer
Example is applied to be described in detail.
Main agents and specification used in preferred embodiment: dimethylamine, diethylamine, ethanol amine, n-formyl sarcolysine ethylethanolamine, two
Ethanol amine, pyrrolidines, piperidines, morpholine, acetonitrile, methylene chloride (Chongqing chemical reagent head factory, AR)；Piperazine anhydrous, N- methyl piperazine
The bromo- 1- propyl alcohol of piperazine, N- hydroxyethyl piperazine, N-Boc- piperazine, N- phenylpiperazine, 3-, imidazoles, 2-methylimidazole, 4-methylimidazole,
Pyrazoles, 3,5- dimethyl pyrazole, benzimidazole, 1,2,3- triazole, 1,2,4- triazole, benzotriazole, amino -1,2 3-,
4- triazole, 3- amino -5- sulfydryl -1,2,4- triazole, 1-H- tetrazole, 5- methyl tetrazole, 5- phenyl tetrazole, 5- first
Mercapto tetrazole (Shanghai Da Rui Fine Chemical Co., Ltd, > 98%)；1- hydroxyl-benzotriazole (the covalent subject in Shanghai
Skill company, technical grade)；Dihydroartemisinine (Wuling Shan Mountain pharmaceutical Co. Ltd, Chongqing Holley, AR)；(Shanghai reaches auspicious fine bromoethanol
Chemical Co., Ltd., AR)；46.5%BF3.Et2O (Shanghai crystalline substance pure reagent Co., Ltd, AR)；Remaining reagent is commercially available chemistry
Pure or analysis net product, not purified direct use.
Key instrument and model used in preferred embodiment: accurate micro melting point apparatus (X-6, the triumphant instrument of Beijing good fortune
Co., Ltd)；Digital automatic polarimeter (WZZ-2S, Shanghai Precision Scientific Apparatus Co., Ltd)；Superconduction NMR spectrum
Instrument (AV-300, Bruker, Switzerland)；High-resolution mass spectrometer (HR ESI MS) (Varian7.0T, Varian, USA).
The synthesis of embodiment 1, DHA amine derivant
1, the synthesis of DHA fatty amines derivative 1
DHA fatty amines derivative 1a-1h is according to document (Chong Wu, et al.Design, Synthesis and
Evaluation of the Antibacterial Enhancement Activities of Amino
Dihydroartemisinin Derivatives.Molecules, 2013,18,6866-6882) described in compound 4a-4u
Preparation method prepared.
2, the synthesis of DHA piperazine derivative 2
1) synthesis of intermediate M1
Intermediate M1 according to Chinese patent 104418864B (conjugate of dihydroartemisinine and carbostyril compound and its
Preparation method and application) described in the preparation method of intermediate compound I M1 and IM2 prepare.
2) synthesis of DHA piperazine derivative 2a-1~2a-5 and 2b-1~2b-5
M1, CH are sequentially added in 100mL round-bottomed flask3CN、K2CO3And piperazine or substituted-piperazinyl, temperature control stirring react,
TLC monitors reaction process.After reaction, CH is added2Cl215mL and saturation NaCl aqueous solution 20mL, stratification, water layer are used
CH2Cl2(10mL × 2) extraction merges organic phase, saturated salt solution 20mL washing, anhydrous Na2SO4Dry, vacuum rotary steam removes
CH2Cl2Crude product or sterling are obtained, column chromatographs when necessary, and it is dry, up to target compound 2.Specific synthesis condition and it the results are shown in Table 1.
The synthesis condition and result of 1 target compound 2 of table
2 characterize data of target compound is as follows:
2a-1:1H NMR(300MHz,CDCl3) δ: 0.90 (3H, d, J=7.5Hz, H-13), 0.95 (3H, d, J=
6.6Hz, H-14), 1.43 (3H, s, H-15), 1.22-2.06 (10H, m, H-2, H-3, H-7~H-10), 2.37-2.60 (12H,
M, H-1, H-11, H-17~H-19), 3.52-3.59 (1H, m, H-16), 3.91-3.98 (1H, m, H-16), 4.80 (1H, s, H-
12),5.45(1H,s,H-5).
2a-2:1H NMR(300MHz,CDCl3) δ: 0.90 (3H, d, J=7.5Hz, H-13), 0.96 (3H, d, J=
6.6Hz, H-14), 1.43 (3H, s, H-15), 1.46 (9H, s, H-22), 1.22-2.06 (10H, m, H-2, H-3, H-7~H-
10), 2.30 (3H, s, H-20), 2.37-2.60 (12H, m, H-1, H-11, H-17~H-19), 3.52-3.59 (1H, m, H-
16),3.91-3.98(1H,m,H-16),4.80(1H,s,H-12),5.45(1H,s,H-5).
2a-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.89 (3H, d, J=7.3Hz, H-13), 0.95 (3H, d, J=6.0Hz, H-14), 1.42 (3H, s, H-15), 1.15-2.06
(10H, m, H-2, H-3, H-7~H-10), 2.28-2.59 (14H, m, H-1, H-11, H-17~H-20), 3.36-4.43 (1H,
M, H-16), 3.62 (2H, t, J=5.3Hz, H-21), 3.84-3.91 (1H, m, H-16), 4.77 (1H, d, J=3.3Hz, H-
12),5.30(1H,s,H-22),5.38(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:103.98(C-4),101.90(C-
12),87.84(C-5),81.07(C-6),68.54(C-16),59.36(C-22),57.72(C-20),55.52(C-17),
53.26(C-19),52.45(C-1),46.76(C-18),44.31(C-7),37.39(C-11),36.32(C-10),34.57
(C-3),30.76(C-9),26.12(C-8),24.63(C-15),24.30(C-2),20.29(C-14),13.01(C-13).HR
MS:C23H40N2O6[M+H]+Calculated value 441.2959, measured value 441.2954.
2a-4:m.p.:107.8-109.1℃； 1H NMR(300MHz,
CDCl3) δ: 0.90 (3H, d, J=7.2Hz, H-13), 0.96 (3H, d, J=6.0Hz, H-14), 1.43 (3H, s, H-15),
1.46 (9H, s, H-22), 1.22-2.06 (10H, m, H-2, H-3, H-7~H-10), 2.32-2.65 (8H, m, H-1, H-11, H-
17and H-18),3.40-3.44(4H,m,H-19),3.52-3.58(1H,m,H-16),3.92-4.00(1H,m,H-16),
4.80(1H,s,H-12),5.46(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:154.6(C-21),104.0(C-4),
101.9(C-12),87.8(C-5),81.0(C-6),79.7(C-22),66.0(C-16),57.9(C-17),53.5(C-19),
52.0(C-1),49.2(C-18),44.4(C-7),37.4(C-11),36.4(C-10),34.6(C-3),30.8(C-9),28.4
(C-23),26.4(C-17),26.1(C-8),24.6(C-15),24.4(C-2),20.4(C-14),13.0(C-13).HR MS:
C27H40N2O5[M+H]+Calculated value 497.3221, measured value 497.3222.
2a-5:m.p.:90.0-91.7℃； 1H NMR(300MHz,
CDCl3) δ: 0.90 (3H, d, J=7.2Hz, H-13), 0.95 (3H, d, J=6.0Hz, H-14), 1.44 (3H, s, H-15),
1.23-2.06 (10H, m, H-2, H-3, H-7~H-10), 2.32-2.42 (1H, m, H-1), 2.59-2.70 (7H, m, H-11, H-
17and H-18), 3.21 (4H, t, J=7.5Hz, H-19), 3.58-3.65 (1H, m, H-16), 3.98-4.05 (1H, m, H-
16), 4.83 (1H, d, J=2.7Hz, H-12), 5.48 (1H, s, H-5), 6.89 (1H, t, J=7.2Hz, H-23), 6.94 (2H,
D, J=7.8Hz, H-21), 7.25-7.30 (2H, m, H-22)；13C NMR(75MHz,CDCl3)δ:151.3(C-20),129.1
(C-22),120.0(C-23),116.0(C-21),104.0(C-4),102.0(C-12),87.9(C-5),81.1(C-6),
66.0(C-16),57.9(C-17),53.5(C-19),52.6(C-1),49.2(C-18),44.4(C-7),37.5(C-11),
36.4(C-10),34.7(C-3),30.9(C-9),26.2(C-8),24.7(C-15),24.4(C-2),20.3(C-14),13.1
(C-13).HR MS:C27H40N2O5(M+H)+Calculated value 473.3010, measured value 473.3014.
2b-1: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.89 (3H, d, J=7.2Hz, H-13), 0.96 (3H, d, J=6.0Hz, H-14), 1.44 (3H, s, H-15), 1.26-2.06
(12H, m, H-2, H-3, H-7~H-10and H-17), 2.37-2.62 (12H, m, H-1, H-11, H-18~H-20), 3.37-
3.44(1H,m,H-16),3.84-3.92(1H,m,H-16),4.77(1H,s,H-12),5.39(1H,s,H-5).
2b-2: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.89 (3H, d, J=7.2Hz, H-13), 0.96 (3H, d, J=6.0Hz, H-14), 1.44 (3H, s, H-15), 1.26-2.06
(12H, m, H-2, H-3, H-7~H-10and H-17), 2.30 (3H, s, H-20), 2.37-2.62 (12H, m, H-1, H-11, H-
18~H-20), 3.37-3.44 (1H, m, H-16), 3.84-3.92 (1H, m, H-16), 4.77 (1H, s, H-12), 5.39 (1H,
s,H-5)；13C NMR(75MHz,CDCl3)δ:104.1(C-4),101.9(C-12),87.8(C-5),81.0(C-6),66.5
(C-16),55.5(C-18),55.0(C-19),53.1(C-20),52.5(C-21),46.0(C-1),44.4(C-7),37.1
(C-11),36.4(C-10),34.6(C-3),30.9(C-9),27.0(C-17),26.2(C-8),24.6(C-15),24.4(C-
2),20.3(C-14),13.0(C-13).HR MS:C23H40N2O5[M+H]+Calculated value 425.3010, measured value 425.3010.
2b-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.89 (3H, d, J=7.3Hz, H-13), 0.95 (3H, d, J=6.0Hz, H-14), 1.42 (3H, s, H-15), 1.15-2.06
(12H, m, H-2, H-3, H-7~H-10and H-17), 2.28-2.59 (14H, m, H-1, H-11, H-17~H-20), 3.36-
3.43 (1H, m, H-16), 3.62 (2H, t, J=5.3Hz, H-21), 3.84-3.91 (1H, m, H-16), 4.77 (1H, d, J=
3.3Hz,H-12),5.30(1H,s,H-23),5.38(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:104.00(C-4),
101.90(C-12),87.81(C-5),81.04(C-6),66.43(C-16),59.31(C-22),57.68(C-20),55.42
(C-17),53.06(C-19),52.76(C-18),52.49(C-1),44.35(C-7),37.42(C-11),36.35(C-10),
34.56(C-3),30.84(C-9),26.97(C-17),26.12(C-8),24.61(C-15),24.40(C-2),20.30(C-
14),12.97(C-13).HR MS:C24H42N2O6[M+H]+Calculated value 455.3116, measured value 455.3115.
2b-4: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.90 (3H, d, J=7.5Hz, H-13), 0.96 (3H, d, J=6.0Hz, H-14), 1.43 (3H, s, H-15), 1.47 (9H, s,
), H-23 1.26-2.06 (12H, m, H-2, H-3, H-7~H-10and H-17), 2.32-2.43 (1H, m, H-1), 2.61-
2.64 (1H, m, H-11), 3.40-3.46 (11H, m, H-16, H-18~H-20), 3.92-4.00 (1H, m, H-16), 4.19
(2H, t, J=6.3Hz, H-14), 4.76 (1H, s, H-12), 5.37 (1H, s, H-5)；13C NMR(75MHz,CDCl3)δ:
154.6(C-21),104.0(C-4),101.9(C-12),87.8(C-5),81.0(C-6),79.7(C-22),66.5(C-16),
55.3(C-18),52.6(C-20),52.5(C-19),52.0(C-1),44.4(C-7),37.4(C-11),36.4(C-10),
34.6(C-3),30.8(C-9),28.4(C-23),26.4(C-17),26.1(C-8),24.6(C-15),24.4(C-2),20.4
(C-14),13.0(C-13).HR MS:C27H46N2O7[M+H]+Calculated value 511.3378, measured value 511.3370.
2b-5:1H NMR(300MHz,CDCl3) δ: 0.92 (3H, d, J=7.5Hz, H-13), 0.96 (3H, d, J=
5.7Hz, H-14), 1.44 (3H, s, H-15), 1.23-2.06 (12H, m, H-2, H-3, H-7~H-10and H-17), 2.32-
2.42(1H,m,H-1),2.49-2.65(7H,m,H-11,H-18and H-19),3.22-3.25(4H,m,H-20),3.40-
3.48 (1H, m, H-16), 3.88-3.96 (1H, m, H-16), 4.80 (1H, d, J=2.4Hz, H-12), 5.41 (1H, s, H-5),
6.87 (1H, t, J=7.2Hz, H-23), 6.94 (2H, d, J=7.8Hz, H-21), 7.25-7.30 (2H, m, H-22)；13C NMR
(75MHz,CDCl3)δ:151.2(C-21),129.1(C-23),119.7(C-24),116.0(C-22),104.0(C-4),
102.0(C-12),87.9(C-5),81.1(C-6),66.5(C-16),55.6(C-18),53.2(C-20),52.6(C-1),
49.1(C-19),44.4(C-7),37.5(C-11),36.4(C-10),34.6(C-3),30.9(C-9),28.4(C-17),
26.2(C-8),24.7(C-15),24.5(C-2),20.4(C-14),13.0(C-13).HR MS:C28H42N2O5[M+H]+It calculates
Value 487.3167, measured value 487.3162.
The synthesis of embodiment 2, DHA azole derivative
Sequentially added in 100mL round-bottomed flask azole compounds YH, N,N-dimethylformamide (DMF) and alkali (NaH or
K2CO3), after stirring 15min, M1, temperature control stirring reaction is added, TLC monitors reaction process.After the reaction was completed, ethyl acetate is added
(EtOAc) 15mL and saturation NaCl aqueous solution 20mL, stratification, water layer are extracted with EtOAc (10mL × 2), merge organic phase,
Saturated salt solution 20mL washing, anhydrous Na2SO4Dry, vacuum rotary steam removes EtOAc and obtains crude product or sterling, and column chromatographs when necessary,
It is dry, up to target compound 3,4,5.Specific synthesis condition and it the results are shown in Table 2,3,4.
The synthesis condition and result of 2 target compound 3 of table
The synthesis condition and result of 3 target compound 4 of table
The synthesis condition and result of 4 target compound 5 of table
The characterize data of target compound 3-5 is as follows:
3a-1:m.p.:93.7-95.1℃； 1H NMR(300MHz,
CDCl3) δ: 0.80 (3H, d, J=7.4Hz, H-14), 0.93 (3H, d, J=5.5Hz, H-13), 1.42 (3H, s, H-15),
1.17-2.08 (10H, m, H-2, H-3, H-7~H-10), 2.34 (1H, td, J=14.0,3.9Hz, H-1), 2.51-2.65
(1H, m, H-11), 3.68-3.81 (1H, m, H-16), 4.19-4.41 (3H, m, H-16and H-17), 4.75 (1H, d, J=
3.4Hz,H-12),5.13(1H,s,H-5),6.23(s,1H,H-19),7.42(1H,s,H-20),7.51(1H,s,H-20)；13C
NMR(75MHz,CDCl3)δ:139.29(C-20),129.67(C-19),105.16(C-18),103.98(C-4),101.87
(C-12),87.70(C-5),80.89(C-6),66.66(C-16),52.37(C-1),51.99(C-17),44.10(C-7),
37.11(C-11),36.29(C-10),34.46(C-3),30.62(C-9),26.08(C-8),24.57(C-15),24.14(C-
2),20.29(C-14),12.81(C-13).HR MS:C20H30N2O5(M+Na)+Calculated value 401.2047, measured value
401.2050.
3a-2: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.85 (3H, d, J=7.2Hz, H-14), 0.94 (3H, d, J=6.1Hz, H-13), 1.44 (3H, s, H-15), 1.22-2.07
(10H, m, H-2, H-3, H-7~H-10), 2.32-2.38 (1H, m, H-1), 2.61-2.63 (1H, m, H-11), 3.62-3.68
(1H,m,H-16),4.15-4.21(3H,m,H-16and H-17),4.76(1H,s,H-12),5.11(1H,s,H-5),7.00
(1H,s,H-19),7.09(1H,s,H-18),7.62(1H,s,H-20)；13C NMR(75MHz,CDCl3)δ:128.7(C-20),
123.1(C-19),118.9(C-18),104.1(C-4),102.0(C-12),87.8(C-5),80.8(C-6),67.0(C-
16),52.3(C-1),47.2(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),
26.1(C-8),24.6(C-15),24.3(C-2),20.3(C-14),13.0(C-13).HR MS:C20H30N2O5(M+H)+It calculates
Value 379.2228, measured value 379.2221.
3a-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:0.91
(3H, d, J=6.9Hz, H-14), 0.95 (3H, d, J=6.3Hz, H-13), 1.45 (3H, s, H-15), 1.19-2.06 (10H,
M, H-2, H-3, H-7~H-10), 2.12 (3H, s, H-21), 2.32-2.43 (1H, m, H-1), 2.59-2.66 (1H, m, H-
11), 3.40-3.52 (4H, m, H-16and H-17), 4.69 (1H, d, J=2.7Hz, H-12), 5.39 (1H, s, H-5)；13C
NMR(75MHz,CDCl3)δ:127.8(C-18),127.2(C-20),118.8(C-19),104.2(C-4),102.0(C-12),
87.8(C-5),80.9(C-6),66.9(C-16),52.4(C-1),47.8(C-17),44.0(C-7),37.2(C-11),36.3
(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-
13),12.7(C-21).HR MS:C21H32N2O5(M+H)+Calculated value 393.2384, measured value 393.2382.
3a-4: yellow oil； 1H NMR(300MHz,CDCl3)δ:0.85
(3H, d, J=7.2Hz, H-14), 0.94 (3H, d, J=4.8Hz, H-13), 1.43 (3H, s, H-15), 1.22-2.07 (10H,
M, H-2, H-3, H-7~H-10), 2.29-2.34 (1H, m, H-1), 2.41 (3H, s, H-21), 2.61-2.63 (1H, m, H-
11), 3.58-3.63 (1H, m, H-16), 3.99-4.16 (3H, m, H-16and H-17), 4.76 (1H, d, J=3.3Hz, H-
12),5.08(1H,s,H-5).6.88(1H,s,H-19),6.92(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:126.7
(C-20and C-19),118.9(C-18),104.2(C-4),102.0(C-12),87.8(C-5),80.9(C-6),66.8(C-
16),52.4(C-1),45.8(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),
26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),12.9(C-21).HR MS:
C21H32N2O5(M+H)+Calculated value 393.2384, measured value 393.2386.
3a-5: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.81 (3H, d, J=7.2Hz, H-14), 0.87 (3H, d, J=6.3Hz, H-13), 1.42 (3H, s, H-15), 1.26-2.08
(10H, m, H-2, H-3, H-7~H-10), 2.29-2.37 (1H, m, H-1), 2.21 (3H, s, H-21), 2.28 (3H, s, H-
22),2.51-2.59(1H,m,H-11),3.64-3.69(1H,m,H-16),4.12-4.28(3H,m,H-16and H-17),
4.75 (1H, d, J=2.7Hz, H-12), 5.07 (1H, s, H-5) .5.86 (1H, s, H-19)；13C NMR(75MHz,CDCl3)δ:
147.4(C-20),139.4(C-19),104.6(C-4),103.9(C-19),101.7(C-12),87.6(C-5),80.9(C-
6),66.4(C-16),52.3(C-1),47.9(C-17),44.2(C-7),37.0(C-11),36.3(C-10),34.6(C-3),
30.7(C-9),26.1(C-8),24.5(C-15),24.0(C-2),20.2(C-14),13.0(C-13),12.8(C-21),
11.1(C-22)；HR MS:C22H34N2O5(M+Na)+Calculated value 429.2360, measured value 429.2356.
3a-6: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.76 (3H, d, J=7.5Hz, H-14), 0.83 (3H, d, J=6.0Hz, H-13), 1.39 (3H, s, H-15), 1.15-1.99
(10H, m, H-2, H-3, H-7~H-10), 2.24-2.35 (H, m, H-1), 2.52-2.59 (H, m, H-11), 3.70-3.76
(1H, m, H-16), 4.28-4.43 (3H, m, H-16and H-17), 4.73 (1H, d, J=2.7Hz, H-12), 4.91 (1H, s,
), H-5 7.30 (2H, t, J=2.4Hz, H-21and H-22), 7.42 (1H, d, J=7.5Hz, H-23), 7.80 (1H, d, J=
7.5Hz,H-20),7.95(1H,s,H-18).
3b-1:m.p.:109.3-110.2℃； 1H NMR(300MHz,
CDCl3) δ: 0.94 (3H, d, J=6.9Hz, H-14), 0.96 (3H, d, J=5.6Hz, H-13), 1.44 (3H, s, H-15),
1.17-2.22 (12H, m, H-2, H-3, H-7~H-10and H-17), 2.37 (1H, m, H-1), 2.59-2.72 (1H, m, H-
11), 3.28-3.36 (1H, m, H-16), 3.82-3.89 (1H, m, H-16), 4.23 (2H, t, J=7.0Hz, H-18), 4.78
(1H, d, J=3.3Hz, H-12), 5.40 (1H, s, H-5), 6.25 (1H, s, H-20), 7.37 (1H, s, H-19), 7.52 (1H,
s,H-21)；13C NMR(75MHz,CDCl3)δ:139.31(C-21),129.09(C-20),105.25(C-19),104.06(C-
4),102.01(C-12),87.84(C-5),81.00(C-6),64.96(C-16),52.47(C-1),49.00,44.29(C-
7),37.38(C-11),36.33(C-10),34.54(C-3),30.82(C-17),30.49(C-9),26.13(C-8),24.62
(C-15),24.46(C-2),20.33(C-14),13.09(C-13).HR MS:C21H32N2O5(M+Na)+Calculated value
415.2203 measured value 415.2202.
3b-2: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.94-0.98 (6H, m, H-13and H-14), 1.43 (3H, s, H-15), 1.25-2.06 (12H, m, H-2, H-3, H-7~H-
10and H-17),2.33-2.42(1H,m,H-1),2.60-2.71(1H,m,H-11),3.33-3.40(1H,m,H-16),
3.83-3.90 (1H, m, H-16), 4.04 (2H, t, J=7.2Hz, H-18), 4.78 (1H, s, H-12), 5.37 (1H, s, H-5),
6.91(1H,s,H-20),7.07(1H,s,H-19),7.47(1H,s,H-21)；13C NMR(75MHz,CDCl3)δ:137.1
(21),129.5(C-20),118.8(C-19),104.1(C-4),102.0(C-12),87.9(C-5),80.9(C-6),64.4
(C-16),52.5(C-1),44.2(C-7),43.8(C-18),37.5(C-11),36.3(C-10),34.5(C-3),31.2(C-
17),30.8(C-9),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.1(C-13).HR MS:
C21H32N2O5[M+H]+Calculated value 393.2384, measured value 393.2386.
3b-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:0.91
(3H, d, J=6.9Hz, H-14), 0.95 (3H, d, J=6.3Hz, H-13), 1.45 (3H, s, H-15), 1.19-2.06 (12H,
M, H-2, H-3, H-7~H-10and H-17), 2.13 (3H, s, H-22), 2.32-2.43 (1H, m, H-1), 2.59-2.66
(1H, m, H-11), 3.40-3.52 (4H, m, H-16and H-18), 4.69 (1H, d, J=2.7Hz, H-12), 5.39 (1H, s,
H-5)；13C NMR(75MHz,CDCl3)δ:127.9(C-19),127.2(C-21),118.9(C-20),104.2(C-4),
102.0(C-12),87.8(C-5),80.9(C-6),66.9(C-16),52.4(C-1),47.8(C-18),44.0(C-7),
37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),29.7(C-17),26.1(C-8),24.6(C-15),
24.2(C-2),20.3(C-14),13.0(C-13),12.7(C-21).HRMS:C22H34N2O5[M+H]+Calculated value 407.2540,
Measured value 407.2542.
3b-4: yellow oil； 1H NMR(300MHz,CDCl3)δ:0.85
(3H, d, J=7.2Hz, H-14), 0.94 (3H, d, J=4.8Hz, H-13), 1.43 (3H, s, H-15), 1.22-2.07 (12H,
M, H-2, H-3, H-7~H-10and H-17), 2.29-2.34 (1H, m, H-1), 2.41 (3H, s, H-21), 2.61-2.63
(1H, m, H-11), 3.58-3.63 (1H, m, H-16), 3.99-4.16 (3H, m, H-16and H-17), 4.76 (1H, d, J=
3.3Hz,H-12),5.08(1H,s,H-5).6.88(1H,s,H-20),6.92(1H,s,H-19)；13C NMR(75MHz,
CDCl3)δ:126.7(C-20andC-19),118.9(C-18),104.2(C-4),102.0(C-12),87.8(C-5),80.9
(C-6),66.8(C-16),52.4(C-1),45.8(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-
3),30.6(C-9),29.6(C-17),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),
12.9(C-21).HR MS:C22H34N2O5[M+H]+Calculated value 407.2540, measured value 407.2537.
3b-5: yellow oil； 1H NMR(400MHz,CDCl3)δ:
0.93 (3H, d, J=7.4Hz, H-13), 0.96 (3H, d, J=7.4Hz, H-14), 1.44 (3H, s, H-15), 1.37-2.12
(12H, m, H-2, H-3, H-7~H-10and H-17), 2.21 (3H, s, H-21), 2.29 (3H, s, H-22), 2.39 (1H, m,
H-1),2.61-2.68(1H,m,H-11),3.36-3.41(1H,m,H-16),3.85-3.90(1H,m,H-16),4.03(2H,
T, J=7.1Hz, H-18), 4.80 (1H, d, J=2.4Hz, H-12), 5.45 (1H, s, H-5), 5.77 (1H, s, H-19)；13C
NMR(75MHz,CDCl3)δ:147.18(C-21and C-23),138.39(C-20),104.77(C-4),103.98(C-20),
101.79(C-12),87.81(C-5),80.97(C-6),65.07(C-16),52.44(C-1),45.56(C-17),44.30
(C-7),37.30(C-11),36.31(C-10),34.54(C-3),30.79(C-9),30.53(C-18),26.07(C-8),
24.59(C-15),24.43(C-2),20.27(C-14),13.39(C-13),13.02(C-13),10.85(C-22and C-
23).HR MS:C23H36N2O5[M+Na]+Calculated value 443.2516, measured value 443.2518.
3b-6: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.87 (3H, d, J=6.9Hz, H-13), 0.98 (3H, d, J=7.5Hz, H-14), 1.44 (3H, s, H-15), 1.26-2.16
(12H, m, H-2, H-3, H-7~H-10and H-17), 2.33-2.43 (1H, m, H-1), 2.68-2.71 (1H, m, H-11),
3.39-3.47 (1H, m, H-16), 3.88-3.95 (1H, m, H-16), 4.30 (2H, t, J=7.2Hz, H-18), 4.82 (1H, d,
J=2.4Hz, H-12), 5.40 (1H, s, H-5), 7.30-7.33 (2H, m, H-22and H-23), 7.41 (1H, d, J=
4.8Hz,H-21),7.82-7.85(1H,m,H-24),7.98(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:129.1
(C-21and C-24),116.1(C-22andC-23),104.0(C-4),102.0(C-12),87.8(C-5),81.0(C-6),
66.4(C-16),52.5(C-1),49.0(C-18),44.0(C-7),37.5(C-11),36.4(C-10),34.6(C-3),
30.7(C-9),29.7(C-17),26.2(C-8),24.7(C-15),24.5(C-2),20.4(C-14),13.0(C-13).HR
MS:C25H34N2O5[M+H]+Calculated value 443.2541, measured value 443.2538.
4a-1:m.p.:100.8-102.4℃； 1H NMR(300MHz,
CDCl3) δ: 0.74 (3H, d, J=7.2Hz, H-14), 0.93 (3H, d, J=5.4Hz, H-13), 1.42 (3H, s, H-15),
1.12-2.11 (10H, m, H-2, H-3, H-7~H-10), 2.34 (1H, m, H-1), 2.47-2.63 (1H, m, H-11), 3.89-
3.96(1H,m,H-16),4.33-4.40(1H,m,H-16),4.64(2H,m,H-17),4.77(1H,s,H-12),5.21(1H,
s,H-5),7.60(2H,s,H-18)；13C NMR(75MHz,CDCl3)δ:133.96(C-18),103.97(C-4),102.10
(C-12),87.79(C-5),80.92(C-6),66.12(C-16),54.73(C-17),52.37(C-1),44.12(C-7),
37.13(C-11),36.29(C-10),34.47(C-3),30.58(C-9),26.08(C-8),24.58(C-15),23.93(C-
2),20.31(C-14),12.67(C-13).HR MS:C19H29N3O5[M+Na]+Calculated value 402.1999, measured value
402.1997.
4a-2:m.p.:128.4-129.7℃； 1H NMR(300MHz,
CDCl3) δ: 0.81 (3H, d, J=7.2Hz, H-14), 0.95 (3H, d, J=5.4Hz, H-13), 1.42 (3H, s, H-15),
1.16-2.08 (10H, m, H-2, H-3, H-7~H-10), 2.35 (1H, m, H-1), 2.56-2.65 (1H, m, H-11), 3.77-
3.84(1H,m,H-16),4.26-4.33(1H,m,H-16),4.52-4.60(1H,m,H-17),4.63-4.72(1H,m,H-
17), 4.78 (1H, d, J=3.2Hz, H-12), 5.16 (1H, s, H-5), 7.62 (1H, s, H-18), 7.72 (1H, s, H-19)；13C NMR(75MHz,CDCl3)δ:133.62(C-19),123.94(C-18),104.11(C-4),102.06(C-12),87.77
(C-5),80.78(C-6),66.46(C-16),52.33(C-1),50.12(C-17),43.97(C-7),37.18(C-11),
36.23(C-10),34.35(C-3),30.54(C-9),26.04(C-8),24.51(C-15),24.19(C-2),20.30(C-
14),12.80(C-13).HR MS:C19H29N3O5[M+Na]+Calculated value 402.1999, measured value 402.1993.
4a-3:m.p.:93.5-95.2℃； 1H NMR(300MHz,
CDCl3) δ: 0.78 (3H, d, J=7.2Hz, H-14), 0.94 (3H, d, J=4.5Hz, H-13), 1.42 (3H, s, H-15),
1.19-2.08 (10H, m, H-2, H-3, H-7~H-10), 2.31-2.39 (1H, m, H-1), 2.58-2.62 (1H, m, H-11),
3.74-3.81(1H,m,H-16),4.09-4.17(1H,m,H-16),4.36-4.38(2H,m,H-17),4.78(1H,s,H-
12),5.17(1H,s,H-5),7.96(1H,s,H-19),8.12(1H,s,H-18).
4a-4:m.p.:100.5~104.3 DEG C； 1H NMR(300MHz,
CDCl3) δ: 0.89 (3H, d, J=7.4Hz, H-14), 0.96 (3H, d, J=5.6Hz, H-13), 1.44 (3H, s, H-15),
1.27-2.10 (10H, m, H-2, H-3, H-7~H-10), 2.37 (1H, td, J=14.2,3.7Hz, H-1), 2.63-2.74
(1H, m, H-11), 3.61-3.70 (1H, m, H-16), 4.08-4.23 (3H, m, H-16and H-17), 4.81 (1H, d, J=
3.5Hz,H-12),5.27(1H,s,H-5),7.80(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:154.04,
140.14,104.17,102.24,87.74,80.72,66.47,52.25,43.91,43.51,37.23,36.18,34.25,
30.49,25.95,24.47,24.40,20.21,12.83.HR MS:C19H30N4O5[M+Na]+Calculated value 417.2108, measurement
Value 417.2105.
4a-5:m.p.:97.3-98.5℃； 1H NMR(300MHz,
CDCl3) δ: 0.91 (3H, d, J=7.4Hz, H-14), 0.94 (3H, d, J=6.3Hz, H-13), 1.41 (3H, s, H-15),
1.21-2.09 (10H, m, H-2, H-3, H-7~H-10), 2.37 (1H, td, J=14.1,3.6Hz, H-1), 2.54-2.69
(1H, m, H-11), 3.23 (2H, t, J=5.8Hz, H-17), 3.82-3.66 (1H, m, H-16), 3.98-4.06 (1H, m, H-
16), 4.83 (1H, d, J=3.2Hz, H-12), 5.06 (2H, s, H-20), 5.57 (1H, s, H-5)；13C NMR(75MHz,
CDCl3)δ:163.32,148.19,104.35,101.96,88.16,81.26,67.28,52.40,44.26,37.28,
36.30,34.52,32.05,30.87,25.94,24.52,24.33,20.33,12.93.HR MS:C19H30N4O5S[M-H]-Meter
Calculation value 425.1864, measured value 425.1866.
4a-6:m.p.:139.3-140.5℃； 1H NMR(300MHz,
CDCl3) δ: 0.63 (3H, d, J=7.5Hz, H-13), 0.85 (3H, d, J=6.0Hz, H-14), 1.39 (3H, s, H-15),
0.97-1.99 (10H, m, H-2, H-3, H-7~H-10), 2.23-2.34 (1H, m, H-1), 2.47-2.50 (1H, m, H-11),
3.88-3.93 (1H, m, H-16), 4.45-4.52 (1H, m, H-16), 4.73 (1H, d, J=3.0Hz, H-12), 4.80-4.93
(3H, m, H-5and H-17), 7.37 (1H, t, J=7.5Hz, H-21), 7.49 (1H, t, J=7.2Hz, H-20), 7.57 (1H,
D, J=8.1Hz, H-19), 7.86 (2H, d, J=8.4Hz, H-22)；13C NMR(75MHz,CDCl3)δ:145.8(C-23),
133.5(C-18),127.1(C-21),123.8(C-20),119.8(C-22),109.6(C-19),104.0(C-4),102.0
(C-12),87.6(C-5),80.7(C-6),66.1(C-16),52.2(C-1),48.0(C-17),43.9(C-7),36.9(C-
11),36.2(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.4(C-15),24.0(C-2),20.2(C-14),
12.6(C-13).HR MS:C23H31N3O5[M+Na]+Calculated value 452.2156, measured value 452.2151.
4a-7:m.p.:65.6-67.3℃； 1H NMR(300MHz,
CDCl3) δ: 0.73 (3H, d, J=6.9Hz, H-13), 0.87 (3H, d, J=7.5Hz, H-14), 1.42 (3H, s, H-15),
1.01-1.99 (10H, m, H-2, H-3, H-7~H-10), 2.25-2.33 (1H, m, H-1), 2.49-2.55 (1H, m, H-11),
4.00-4.04(1H,m,H-16),4.62-4.68(1H,m,H-16),4.81(1H,s,H-12),4.89-5.03(3H,m,H-
5and H-17), 7.38 (1H, d, J=9.0Hz, H-20), 7.86 (2H, d, J=9.3Hz, H-19)；13C NMR(75MHz,
CDCl3)δ:143.5(C-18),126.2(C-20),117.9(C-19),103.9(C-4),101.7(C-12),87.7(C-5),
80.8(C-6),65.5(C-16),56.5(C-17),52.2(C-1),44.0(C-7),36.7(C-11),36.3(C-10),
34.3(C-3),30.6(C-9),26.1(C-8),24.5(C-15),23.9(C-2),20.1(C-14),12.7(C-13).HR
MS:C23H31N3O5[M+Na]+Calculated value 452.2156, measured value 452.2159.
4a-8:m.p.:131.2-132.7℃； 1H NMR(300MHz,
CDCl3) δ: 0.91 (3H, d, J=7.2Hz, H-14), 0.95 (3H, d, J=6.0Hz, H-13), 1.44 (3H, s, H-15),
1.26-2.06 (10H, m, H-2, H-3, H-7~H-10), 2.32-2.43 (H, m, H-1), 2.65-2.72 (H, m, H-11),
3.83~3.90 (1H, m, H-16), 4.22-4.29 (1H, m, H-16), 4.75 (2H, t, J=3.6Hz, H-17), 4.87 (1H,
S, H-12), 5.45 (1H, s, H-5), 7.40 (1H, t, J=7.5Hz, H-21), 7.52 (1H, t, J=7.5Hz, H-20), 7.62
(1H, d, J=8.4Hz, H-22), 8.03 (1H, d, J=8.4Hz, H-19)；13C NMR(75MHz,CDCl3)δ:143.5(C-
23),127.9(C-18),127.4(C-19),124.6(C-21),120.3(C-20),108.6(C-22),104.1(C-4),
102.3(C-12),88.0(C-5),81.0(C-6),79.7(C-17),65.5(C-16),52.5(C-1),44.3(C-7),
37.3(C-11),36.3(C-10),34.5(C-3),30.7(C-9),26.1(C-8),24.6(C-15),24.3(C-2),20.3
(C-14),12.9(C-13).HR MS:C23H31N3O6[M+Na]+Calculated value 468.2105, measured value 468.2098.
4b-1:m.p.:100.8-102.4℃； 1H NMR(300MHz,
CDCl3) δ: 0.94 (3H, d, J=7.2Hz, H-14), 0.96 (3H, d, J=6.2Hz, H-13), 1.43 (3H, s, H-15),
1.17-2.10 (10H, m, H-2, H-3, H-7~H-10), 2.16-2.28 (2H, m, H-17), 2.37 (1H, m, H-1), 2.56-
2.72(1H,m,H-11),3.26-3.43(1H,m,H-16),3.81-3.88(1H,m,H-16),4.54(2H,m,H-18),
4.79 (1H, d, J=3.2Hz, H-12), 5.44 (1H, s, H-5), 7.59 (2H, s, H-18)；13C NMR(75MHz,CDCl3)δ:
133.98(C-19),104.00(C-4),102.09(C-12),87.85(C-5),81.05(C-6),64.78(C-16),52.51
(C-17),51.86(C-1),44.34(C-7),37.29(C-11),36.36(C-10),34.59(C-3),30.84(C-9),
29.88(C-18),26.15(C-8),24.64(C-15),24.43(C-2),20.35(C-14),13.01(C-13).HR MS:
C20H31N3O5[M+Na]+Calculated value 416.2156, measured value 416.2155.
4b-2:m.p.:100.8-102.4℃； 1H NMR(300MHz,
CDCl3) δ: 0.94 (3H, d, J=7.2Hz, H-14), 0.96 (3H, d, J=6.1Hz, H-13), 1.43 (3H, s, H-15),
1.21-2.25 (12H, m, H-2, H-3, H-7~H-10and H-17), 2.28-2.43 (1H, m, H-1), 2.65 (1H, m, H-
11),3.31-3.43(1H,m,H-16),3.83-3.94(1H,m,H-16),4.46-4.52(2H,m,H-17),4.78(1H,d,
J=3.2Hz, H-12), 5.40 (1H, s, H-5), 7.56 (1H, s, H-18), 7.72 (1H, s, H-19)；13C NMR(75MHz,
CDCl3)δ:133.77(C-20),123.48(C-19),104.10(C-4),102.04(C-12),87.84(C-5),80.94
(C-6),64.52(C-16),52.41(C-1),47.19(C-17),44.18(C-7),37.34(C-11),36.27(C-10),
34.46(C-3),30.75(C-9),30.41(C-18),26.08(C-8),24.56(C-15),24.45(C-2),20.31(C-
14),13.04(C-13).HR MS:C20H31N3O5[M+Na]+Calculated value 416.2156, measured value 416.2157.
4b-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.92-0.97 (6H, m, H-14and H-13), 1.43 (3H, s, H-15), 1.19-2.08 (10H, m, H-2, H-3, H-7~H-
10),2.16-2.19(2H,m,H-17),2.32-2.36(1H,m,H-1),2.64-2.67(1H,m,H-11),3.32-3.40
(1H, m, H-16), 3.84-3.91 (1H, m, H-16), 4.28 (2H, t, J=6.9Hz, H-18), 4.77 (1H, s, H-12),
5.39(1H,s,H-5),7.96(1H,s,H-20),8.09(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:151.9(C-
20),143.0(19),104.1(C-4),102.0(C-12),87.8(C-5),80.9(C-6),64.5(C-16),52.4(C-
1),46.7(C-18),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),30.7(C-9),29.9(C-18),
26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C20H31N3O5[M+Na]+Meter
Calculation value 416.2156, measured value 416.2155.
4b-4: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.93 (3H, d, J=7.4Hz, H-14), 0.96 (3H, d, J=5.1Hz, H-13), 1.43 (3H, s, H-15), 1.25-2.15
(12H, m, H-2, H-3, H-7~H-10and H-17), 2.37 (1H, td, J=14.0,3.8Hz, H-1), 2.62-2.71 (1H,
m,H-11),3.55-3.62(1H,m,H-16),3.84-3.92(1H,m,H-16),3.97-4.08(2H,m,H-18),4.81
(1H, d, J=3.3Hz, H-12), 5.44 (1H, s, H-5), 7.65 (1H, s, H-19)；13C NMR(75MHz,CDCl3)δ:
153.99,142.09,104.21,101.97,87.84,80.88,64.67,52.43,46.28,44.22,37.41,36.26,
34.45,30.77,29.32,26.04,24.59,24.46,20.28,13.06.HR MS:C20H32N4O5[M+Na]+Calculated value
431.2265 measured value 431.2266.
4b-5: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.91 (3H, d, J=7.4Hz, H-14), 0.94 (3H, d, J=6.3Hz, H-13), 1.41 (3H, s, H-15), 1.21-2.09
(12H, m, H-2, H-3, H-7~H-10and H-17), 2.37 (1H, td, J=14.1,3.6Hz, H-1), 2.54-2.69 (1H,
M, H-11), 3.23 (2H, t, J=5.8Hz, H-18), 3.66-3.82 (1H, m, H-16), 3.98-4.06 (1H, m, H-16),
4.80 (1H, d, J=3.2Hz, H-12), 5.44 (2H, s, H-21), 5.57 (1H, s, H-5)；13C NMR(75MHz,CDCl3)δ:
163.55,148.20,104.21,101.97,87.93,80.93,64.67,52.43,44.22,37.40,36.31,34.50,
30.87,29.65,26.11,24.59,24.46,20.31,13.06.HR MS:C20H32N4O5S[M+Na]+Calculated value
463.1986 measured value 463.1986.
4b-6: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.94 (3H, d, J=7.5Hz, H-13), 0.97 (3H, d, J=6.9Hz, H-14), 1.42 (3H, s, H-15), 1.21-2.06
(10H, m, H-2, H-3, H-7~H-10), 2.31-2.44 (3H, m, H-1and H-17), 2.60-2.70 (1H, m, H-11),
3.37-3.45(1H,m,H-16),3.86-3.93(1H,m,H-16),4.79-4.87(3H,m,H-12and H-18),5.50
(1H,s,H-5),7.37-7.41(2H,m,H-21),7.84-7.88(2H,m,H-20)；13C NMR(75MHz,CDCl3)δ:
144.3(C-19),126.3(C-21),117.9(C-20),104.0(C-4),102.1(C-12),87.9(C-5),81.1(C-
6),64.8(C-16),53.7(C-18),52.6(C-1),44.4(C-7),37.3(C-11),36.4(C-10),34.6(C-3),
30.7(C-9),26.2(C-8),24.7(C-15),24.5(C-2),22.7(C-17),20.4(C-14),13.0(C-13).HR
MS:C24H33N3O5[M+Na]+Calculated value 466.2312, measured value 466.2309.
4b-7: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.95-0.98 (6H, m, H-13and H-14), 1.43 (3H, s, H-15), 1.26-2.09 (10H, m, H-2, H-3, H-7~H-
10),2.28-2.42(3H,m,H-1and H-17),2.65-2.70(1H,m,H-11),3.41-3.48(1H,m,H-16),
3.88-3.95 (1H, m, H-16), 4.72-4.78 (2H, m, H-18), 4.81 (1H, d, J=3.3Hz, H-12), 5.44 (3H, s,
), H-5 7.38 (1H, t, J=7.5Hz, H-21), 7.46-7.55 (2H, m, H-22and H-23), 8.08 (1H, d, J=
7.8Hz,H-20)；13C NMR(75MHz,CDCl3)δ:145.9(C-19),133.0(C-24),127.3(C-21),123.9(C-
22),120.0(C-20),109.2(C-23),104.2(C-4),102.1(C-12),87.9(C-5),81.0(C-6),64.8
(C-16),52.5(C-1),45.3(C-18),44.3(C-7),37.4(C-11),36.3(C-10),34.6(C-3),30.6(C-
9),29.9(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.1(C-13).HR MS:
C24H33N3O5[M+Na]+Calculated value 466.2312, measured value 466.2310.
4b-8:m.p.:106.3-108.1℃； 1H NMR(300MHz,
CDCl3) δ: 0.88 (3H, d, J=9.3Hz, H-14), 0.93 (3H, d, J=7.2Hz, H-13), 1.45 (3H, s, H-15),
1.22-2.03 (10H, m, H-2, H-3, H-7~H-10), 2.13-2.17 (2H, m, H-17), 2.32-2.42 (H, m, H-1),
2.64-2.71 (H, m, H-11), 3.62-3.67 (1H, m, H-16), 4.10~4.18 (1H, m, H-16), 4.66 (2H, t, J=
6.0Hz, H-18), 4.85 (1H, s, H-12), 5.43 (1H, s, H-5), 7.40 (1H, t, J=7.2Hz, H-21), 7.52 (1H,
T, J=7.2Hz, H-22), 7.59 (1H, d, J=7.8Hz, H-23), 8.02 (1H, d, J=8.7Hz, H-20)；13C NMR
(75MHz,CDCl3)δ:143.5(C-24),127.9(C-19),127.3(C-20),124.5(C-22),120.3(C-21),
108.5(C-23),104.1(C-4),102.1(C-12),87.9(C-5),81.0(C-6),77.4(C-18),64.1(C-16),
52.5(C-1),44.3(C-7),37.3(C-11),36.4(C-10),34.5(C-3),30.8(C-9),28.6(C-17),26.1
(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C24H33N3O6[M+Na]+Calculated value
482.2262 measured value 482.2260.
5a-1:m.p.:135.2-136.5℃； 1H NMR(300MHz,
CDCl3) δ: 0.72 (3H, d, J=7.8Hz, H-13), 0.95 (3H, d, J=5.1Hz, H-14), 1.43 (3H, s, H-15),
1.25-2.06 (10H, m, H-2, H-3, H-7~H-10), 2.31-2.40 (1H, m, H-1), 2.63-2.65 (1H, m, H-11),
3.80-3.86 (1H, m, H-16), 4.28-4.35 (1H, m, H-16), 4.63 (2H, t, J=4.8Hz, H-18), 4.79 (1H, s,
H-12),5.19(1H,s,H-5),8.64(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:143.0(C-18),104.2
(C-4),102.3(C-12),87.9(C-5),80.7(C-6),65.7(C-16),52.3(C-1),48.4(C-17),43.9(C-
7),37.3(C-11),36.3(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.5(C-15),24.3(C-2),
20.3(C-14),12.8(C-13).HR MS:C18H28N4O5[M+Na]+Calculated value 403.1952, measured value 403.1951.
5a-2:m.p.:123.2-124.6℃； 1H NMR(300MHz,
CDCl3) δ: 0.72 (3H, d, J=7.5Hz, H-13), 0.95 (3H, d, J=4.8Hz, H-14), 1.43 (3H, s, H-15),
1.24-2.05 (10H, m, H-2, H-3, H-7~H-10), 2.31-2.39 (1H, m, H-1), 2.54-2.61 (1H, m, H-11),
3.96-4.03 (1H, m, H-16), 4.38-4.45 (1H, m, H-16), 4.78 (1H, s, H-12), 4.87 (2H, t, J=4.8Hz,
H-17),5.22(1H,s,H-5),8.52(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:152.8(C-18),104.1
(C-4),102.2(C-12),87.9(C-5),80.9(C-6),65.5(C-16),53.1(C-17),52.4(C-1),44.1(C-
7),37.3(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.0(C-2),
20.3(C-14),12.6(C-13).HR MS:C18H28N4O5[M+Na]+Calculated value 403.1952, measured value 403.1949.
5a-3:m.p.:117.4-119.1℃； 1H NMR(300MHz,
CDCl3) δ: 0.93 (3H, d, J=7.5Hz, H-13), 0.95 (3H, d, J=5.7Hz, H-13), 1.43 (3H, s, H-15),
1.26-2.07 (10H, m, H-2, H-3, H-7~H-10), 2.32-2.42 (1H, m, H-1), 2.56 (1H, s, H-20), 2.62-
2.73(1H,m,H-11),3.41-3.49(1H,m,H-16),3.87-3.94(1H,m,H-16),4.33-4.38(2H,m,H-
18),4.80(1H,s,H-12),5.40(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:162.75,103.96,102.03,
87.79,80.89,64.22,52.46,49.83,44.24,37.22,36.29,34.53,30.73,26.03,24.58,
24.39,20.27,12.90,10.76.HR MS:C19H30N4O5[M+Na]+Calculated value 417.2108, measured value 417.2106.
5a-4:m.p.:114.2-115.7℃； 1H NMR(300MHz,
CDCl3) δ: 0.75 (3H, d, J=7.2Hz, H-14), 0.94 (3H, d, J=4.5Hz, H-13), 1.42 (3H, s, H-15),
1.21-2.04 (10H, m, H-2, H-3, H-7~H-10), 2.29-2.38 (1H, m, H-1), 2.57 (3H, s, H-19), 2.58-
2.61(1H,m,H-11),3.80-3.87(1H,m,H-16),4.34-4.37(1H,m,H-16),4.46-4.48(2H,m,H-
17),4.76(1H,s,H-12),5.11(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:152.1(C-18),104.2(C-
4),102.3(C-12),87.7(C-5),80.7(C-6),65.8(C-16),52.3(C-1),47.0(C-17),43.9(C-7),
37.2(C-11),36.2(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.5(C-15),24.2(C-2),20.3
(C-14),13.0(C-13),8.9(C-19).HR MS:C19H30N4O5[M+Na]+Calculated value 417.2108, measured value
417.2106.
5a-5:m.p.:121.7-123.3℃； 1H NMR(300MHz,
CDCl3) δ: 0.90 (3H, d, J=7.5Hz, H-14), 0.96 (3H, d, J=6.3Hz, H-13), 1.43 (3H, s, H-15),
1.21-2.04 (10H, m, H-2, H-3, H-7~H-10), 2.32-2.43 (H, m, H-1), 2.61-2.66 (H, m, H-11),
3.63 (2H, t, J=5.7Hz, H-17), 3.75-3.83 (1H, m, H-16), 3.93 (3H, s, H-19), 4.12-4.19 (H, m,
), H-16 4.83 (1H, d, J=2.7Hz, H-12), 5.43 (1H, s, H-5)；13C NMR(75MHz,CDCl3)δ:154.0(C-
18),104.1(C-4),102.2(C-12),87.9(C-5),80.9(C-6),66.5(C-16),52.4(C-1),44.2(C-
7),37.4(C-11),36.3(C-10),34.5(C-3),33.6(C-17),33.4(C-19),30.7(C-9),26.1(C-8),
24.6(C-15),24.3(C-2),20.3(C-14),12.9(C-13).HR MS:C19H30N4O5S[M+Na]+Calculated value
449.1829 measured value 449.1821.
5a-6:m.p.:129.8-130.8℃； 1H NMR(300MHz,
CDCl3) δ: 0.87 (3H, d, J=6.9Hz, H-13), 0.98 (3H, d, J=7.5Hz, H-14), 1.44 (3H, s, H-15),
1.26-2.12 (10H, m, H-2, H-3, H-7~H-10), 2.33-2.43 (1H, m, H-1), 2.68-2.71 (1H, m, H-11),
3.94-4.00 (1H, m, H-16), 4.52-4.59 (1H, m, H-16), 4.78-4.82 (1H, m, H-17), 4.83 (1H, d, J=
2.7Hz,H-12),4.91-4.99(1H,m,H-17),5.15(1H,s,H-5),7.47-7.50(3H,m,H-21and H-22),
8.17 (1H, d, J=5.4Hz, H-20)；13C NMR(75MHz,CDCl3)δ:165.1(C-18),130.3(C-22),128.8
(C-21),127.3(C-19),126.7(C-20),104.0(C-4),102.0(C-12),87.8(C-5),80.8(C-6),
64.9(C-16),52.1(C-1),52.3(C-17),44.0(C-7),37.1(C-11),36.3(C-10),34.2(C-3),
30.6(C-9),26.1(C-8),24.4(C-15),24.0(C-2),20.0(C-14),12.87(C-13).HR MS:
C24H32N4O5[M+Na]+Calculated value 479.2265, measured value 479.2268.
5b-1: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.94 (3H, d, J=7.8Hz, H-13), 0.97 (3H, d, J=6.6Hz, H-14), 1.44 (3H, s, H-15), 1.26-2.06
(10H, m, H-2, H-3, H-7~H-10), 2.22-2.28 (2H, m, H-17), 2.33-2.42 (1H, m, H-1), 2.63-2.70
(1H, m, H-11), 3.39-3.46 (1H, m, H-16), 3.87-3.94 (1H, m, H-16), 4.54 (2H, t, J=6.9Hz, H-
18),4.79(H,s,H-12),5.39(1H,s,H-5),8.62(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:142.6
(C-19),104.2(C-4),102.2(C-12),87.9(C-5),80.9(C-6),64.3(C-16),52.4(C-1),45.5
(C-18),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),30.7(C-9),30.0(C-17),26.1(C-
8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C19H30N4O5[M+Na]+Calculated value
417.2108 measured value 417.2111.
5b-2: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.93-0.98 (6H, m, H-13and H-14), 1.43 (3H, s, H-15), 1.26-2.06 (10H, m, H-2, H-3, H-7~H-
10),2.28-2.32(2H,m,H-17),2.37-2.43(1H,m,H-1),2.61-2.68(1H,m,H-11),3.35-3.42
(1H,m,H-16),3.86-3.92(1H,m,H-16),4.74-4.79(3H,m,H-12and H-18),5.41(1H,s,H-5),
8.51(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:152.8(C-19),104.1(C-4),102.2(C-12),87.9
(C-5),81.0(C-6),64.4(C-16),52.5(C-1),50.2(C-18),44.3(C-7),37.4(C-11),36.4(C-
10),34.6(C-3),30.8(C-9),29.5(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),
13.0(C-13).HRMS:C19H30N4O5[M+Na]+Calculated value 417.2108, measured value 417.2114.
5b-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.93 (3H, d, J=7.5Hz, H-13), 0.95 (3H, d, J=5.7Hz, H-13), 1.43 (3H, s, H-15), 1.26-2.07
(10H, m, H-2, H-3, H-7~H-10), 2.16-2.22 (2H, m, H-17), 2.32-2.42 (1H, m, H-1), 2.56 (1H, s,
H-20),2.62-2.73(1H,m,H-11),3.41-3.49(1H,m,H-16),3.87-3.94(1H,m,H-16),4.33-
4.38(2H,m,H-18),4.80(1H,s,H-12),5.40(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:162.75(C-
19),103.96(C-4),102.03(C-12),87.79(C-5),80.89(C-6),64.22(C-16),52.46(C-1),
49.83(C-18),44.24(C-7),37.22(C-11),36.29(C-10),34.53(C-3),30.73(C-9),29.38(C-
17),26.03(C-8),24.58(C-15),24.39(C-2),20.27(C-14),12.90(C-13),10.76(C-20).HR
MS:C20H32N4O5[M+Na]+Calculated value 431.2265, measured value 431.2272.
5b-4: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.93 (3H, d, J=7.5Hz, H-13), 0.97 (3H, d, J=6.1Hz, H-13), 1.44 (3H, s, H-15), 1.19-2.10
(10H, m, H-2, H-3, H-7~H-10), 2.14-2.27 (2H, m, H-17), 2.32-2.47 (1H, m, H-1), 2.57 (3H, s,
H-20),2.64-2.73(1H,m,H-11),3.39-3.59(1H,m,H-16),3.88-3.95(1H,m,H-16),4.33-
4.43 (2H, m, H-18), 4.81 (1H, d, J=3.3Hz, H-12), 5.41 (1H, s, H-5)；13C NMR(75MHz,CDCl3)δ:
104.16(C-4),102.01(C-12),87.87(C-5),80.86(C-6),64.31(C-16),52.42(C-1),44.27
(C-18),44.17(C-7),37.41(C-11),36.30(C-10),34.48(C-3),30.71(C-9),29.72(C-17),
26.04(C-8),24.59(C-15),24.48(C-2),20.26(C-14),12.99(C-13),8.70(C-20).HR MS:
C20H32N4O5[M+Na]+Calculated value 431.2265, measured value 431.2273.
5b-5: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.91 (3H, d, J=7.5Hz, H-13), 0.95 (3H, d, J=6.3Hz, H-13), 1.43 (3H, s, H-15), 1.25-2.06
(12H, m, H-2, H-3, H-7~H-10and H-17), 2.32-2.41 (1H, m, H-1), 2.62-2.67 (1H, m, H-11),
3.42-3.55(3H,m,H-16and H-18),3.92(1H,s,H-20),3.97-4.04(1H,m,H-16),4.80(1H,d,J
=3.0Hz, H-12), 5.39 (1H, s, H-5)；13C NMR(75MHz,CDCl3)δ:154.2(C-19),104.1(C-4),
102.1(C-12),87.9(C-5),81.0(C-6),66.0(C-16),52.4(C-1),44.2(C-7),37.4(C-11),
36.3(C-10),34.5(C-3),33.3(C-18),30.8(C-9),30.3(C-17),29.1(C-20),26.1(C-8),
24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HRMS:C20H32N4O5S[M+Na]+Calculated value
463.1986 measured value 463.1985.
5b-6: white slurry object； 1H NMR(300MHz,CDCl3)δ:
0.87 (3H, d, J=7.2Hz, H-13) .0.96 (3H, d, J=6.7Hz, H-14), 1.43 (3H, s, H-15), 1.12-2.11
(10H, m, H-2, H-3, H-7~H-10), 2.31-2.37 (3H, m, H-1, H-17), 2.62-2.72 (1H, m, H-11), 3.36-
3.54 (1H, m, H-16), 3.97-4.01 (1H, m, H-16), 4.73-4.81 (2H, m, H-18), 4.82 (1H, d, J=2.7Hz,
), H-12 5.46 (1H, s, H-5), 7.42-7.58 (3H, m, H-22and H-23), 8.27-8.07 (2H, d, J=5.4Hz, H-
21)；13C NMR(75MHz,CDCl3)δ:165.11(C-19),130.21(C-23),128.80(C-22),127.40(C-20),
126.81(C-21),104.07(C-4),102.21(C-12),87.87(C-5),80.98(C-6),64.51(C-16),52.52
(C-1),50.28(C-17),44.31(C-7),37.37(C-11),36.37(C-10),34.55(C-3),30.82(C-9),
29.67(C-18),26.12(C-8),24.61(C-15),24.53(C-2),20.31(C-14),12.99(C-13).HR MS:
C25H34N4O5[M+Na]+Calculated value 493.2427, measured value 493.2421.
The anti-Leishmania active testing of embodiment 3, DHA amine derivant and DHA azole derivative
The anti-Leishmania activity of DHA amine derivant and DHA azole derivative is by Lilly Co., Eli. Open
Innovation Drug Discovery (OIDD) program is tested, and carries out single concentration primary dcreening operation (Primary first
SP), more concentration determinations (Primary CRC) then are carried out to the potentiality molecule that preliminary screening goes out.It the results are shown in Table 5.
The anti-Leishmania active testing result of table 5
As known from Table 5, most of life that can inhibit Leishmania donovani (L.donovani) in compound is tested
It is long, under 5 μM of test concentrations, there is the inhibiting rate of 28 compounds to be greater than 30%, 16 compounds (1h, 2a-4,2a-5,3a-6,
3b-5,3b-6,4a-5,4a-7,4b-6,4b-7,4b-8,5a-2,5a-4,5a-5,5b-2,5 b-5) inhibiting rate be not less than
50%, it can be used as and leishmanial drug is resisted further to develop.
Finally, it is stated that preferred embodiment above is only used to illustrate the technical scheme of the present invention and not to limit it, although logical
It crosses above preferred embodiment the present invention is described in detail, however, those skilled in the art should understand that, can be
Various changes are made to it in form and in details, without departing from claims of the present invention limited range.
Claims (7)
1. dihydroqinghaosu shown in Formulas I or its raceme, stereoisomer, tautomer, nitrogen oxides, pharmacy
Upper acceptable salt resists the application in leishmanial drug in preparation:
In Formulas I, n is 1 or 2；
Y is-NR1R2、
R1And R2It independently is H, C1-C3 alkyl or C1-C3 hydroxyalkyl；
R3For H, C1-C3 alkyl, C1-C3 hydroxyalkyl, phenyl substituted or unsubstituted, tertbutyloxycarbonyl, benzyloxycarbonyl group or fatty acyl
Base；Substituent group on the phenyl is one or more, is independently selected from halogen, hydroxyl, amino or C1-C3 alkyl；
R4And R5It independently is H or C1-C3 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C3 alkyl；
R8For H, C1-C3 alkyl, C1-C3 alkylthio group, phenyl substituted or unsubstituted；Substituent group on the phenyl is one or more
It is a, it is independently selected from halogen, hydroxyl, amino or C1-C3 alkyl.
2. application as described in claim 1, it is characterised in that: in Formulas I,
R1And R2It independently is H, C1-C2 alkyl or C1-C2 hydroxyalkyl；
R3For H, C1-C2 alkyl, C1-C2 hydroxyalkyl, phenyl substituted or unsubstituted, tertbutyloxycarbonyl, benzyloxycarbonyl group or alkanoyl；
Substituent group on the phenyl is one or more, is independently selected from halogen, hydroxyl, amino or C1-C2 alkyl；
R4And R5It independently is H or C1-C2 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C2 alkyl；
R8For H, C1-C2 alkyl, C1-C2 alkylthio group, phenyl substituted or unsubstituted；Substituent group on the phenyl is one or more
It is a, it is independently selected from halogen, hydroxyl, amino or C1-C2 alkyl.
3. application as claimed in claim 2, it is characterised in that: in Formulas I,
R1And R2It independently is H, C1-C2 alkyl or C1-C2 hydroxyalkyl；
R3For H, C1-C2 alkyl, C1-C2 hydroxyalkyl, phenyl, tertbutyloxycarbonyl, benzyloxycarbonyl group or acetyl group；
R4And R5It independently is H or C1-C2 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C2 alkyl；
R8For H, C1-C2 alkyl, C1-C2 alkylthio group or phenyl.
4. application as claimed in claim 3, it is characterised in that: in Formulas I,
R1And R2It independently is H, methyl, ethyl or ethoxy；
R3For H, methyl, ethoxy, phenyl or tertbutyloxycarbonyl；
R4And R5It independently is H or methyl；
R6And R7It independently is H or amino；
R8For H, methyl, methyl mercapto or phenyl.
5. application as claimed in claim 4, it is characterised in that: dihydroqinghaosu shown in Formulas I is following compound
Any one of:
6. application as claimed in claim 5, it is characterised in that: dihydroqinghaosu shown in Formulas I is following compound
Any one of: 1h, 2a-4,2a-5,3a-6,3b-5,3b-6,4a-5,4a-7,4b-6,4b-7,4b-8,5a-2,5 a-4,5a-
5,5b-2,5b-5。
7. application as described in claim 1, it is characterised in that: the Leishmania is Leishmania donovani
(Leishmania donovani)。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910785568.1A CN110496121A (en) | 2019-08-23 | 2019-08-23 | Dihydroqinghaosu resists the application in leishmanial drug in preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910785568.1A CN110496121A (en) | 2019-08-23 | 2019-08-23 | Dihydroqinghaosu resists the application in leishmanial drug in preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110496121A true CN110496121A (en) | 2019-11-26 |
Family
ID=68589329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910785568.1A Pending CN110496121A (en) | 2019-08-23 | 2019-08-23 | Dihydroqinghaosu resists the application in leishmanial drug in preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110496121A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114014872A (en) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | Artesunate derivative and preparation method and application thereof |
| CN114933603A (en) * | 2022-06-10 | 2022-08-23 | 上海英诺富成生物科技有限公司 | Artemisinin derivative and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004105772A1 (en) * | 2003-06-03 | 2004-12-09 | Tropmed Gmbh | Pharmaceutical preparation for treating tropical parasitic diseases containing diaminazen-diaceturate and/or pentamidine |
| US20100055201A1 (en) * | 2006-10-27 | 2010-03-04 | Zeligs Michael A | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
| CN106928274A (en) * | 2017-02-28 | 2017-07-07 | 东南大学 | A kind of dihydroartemisinine dliploid derivative, its pharmaceutical composition and application |
| CN107106524A (en) * | 2014-09-02 | 2017-08-29 | 尼奥酷里私人有限公司 | Method for treating protozoal infections |
-
2019
- 2019-08-23 CN CN201910785568.1A patent/CN110496121A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004105772A1 (en) * | 2003-06-03 | 2004-12-09 | Tropmed Gmbh | Pharmaceutical preparation for treating tropical parasitic diseases containing diaminazen-diaceturate and/or pentamidine |
| US20100055201A1 (en) * | 2006-10-27 | 2010-03-04 | Zeligs Michael A | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
| CN107106524A (en) * | 2014-09-02 | 2017-08-29 | 尼奥酷里私人有限公司 | Method for treating protozoal infections |
| CN106928274A (en) * | 2017-02-28 | 2017-07-07 | 东南大学 | A kind of dihydroartemisinine dliploid derivative, its pharmaceutical composition and application |
Non-Patent Citations (6)
| Title |
|---|
| CHONG WU，等: "Design, Synthesis and Evaluation of the Antibacterial Enhancement Activities of Amino Dihydroartemisinin Derivatives", 《MOLECULES》 * |
| CLAUDIO M. LEZAMA-DÁVILA，等: "Leishmanicidal activity of artemisinin, deoxoartemisinin, artemether and arteether", 《NATURAL PRODUCT COMMUNICATIONS》 * |
| MORAKE MOKHITLI，等: "Preliminary Evaluation of Artemisinin-Cholesterol Conjugates as Potential Drugs for the Treatment of Intractable Forms of Malaria and Tuberculosis", 《CHEMMEDCHEM》 * |
| 李洪军，等: "双氢青蒿素抗寄生虫作用研究进展", 《中国血吸虫病防治杂志》 * |
| 欧阳颗，等: "青蒿及其提取物抗原虫作用的研究", 《中国现代医学杂志》 * |
| 芦殿梅，等: "双氢青蒿素对杜氏利什曼原虫前鞭毛体作用体外实验研究", 《中国寄生虫病防治杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114014872A (en) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | Artesunate derivative and preparation method and application thereof |
| CN114933603A (en) * | 2022-06-10 | 2022-08-23 | 上海英诺富成生物科技有限公司 | Artemisinin derivative and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110448552A (en) | Dihydroqinghaosu is preparing the application in antimalarial agent | |
| ES2650915T3 (en) | Amino-substituted Imidazopyridazines | |
| ES2685025T3 (en) | Tetrahydroimidazo [1,5-d] [1,4] oxazepine derivative | |
| ES2908325T3 (en) | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin | |
| BR122023026304A2 (en) | PYRIMIDOHETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUNDS | |
| CN104364254B (en) | Heterobicyclic compounds as beta-lactamase inhibitors | |
| ES2600028T3 (en) | Selective glucosidase inhibitors and their uses | |
| ES2585415T3 (en) | Aminoalkyl-substituted N-thienylbenzamide derivative | |
| CN110496121A (en) | Dihydroqinghaosu resists the application in leishmanial drug in preparation | |
| BR112013013127B1 (en) | PROCESS FOR THE PREPARATION OF MORFOLINIL ANTHRACYCLINE DERIVATIVES, MORFOLINIL ANTHRACYCLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | |
| CA2938050A1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| BR112018067392A2 (en) | wdr5 protein binding inhibitors | |
| WO2015081133A2 (en) | Nucleotides for the treatment of liver cancer | |
| CN107849071A (en) | Antiviral beta amino acids ester phosphono-diamine compound | |
| CN106795199A (en) | As the nucleoside derivates of 4 ' substitutions of hiv reverse transcriptase inhibitor | |
| PT2794604T (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| JP2021075570A (en) | Derivatives of amphotericin B | |
| AU2015243437A1 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| JP6917527B2 (en) | SGLT inhibitors and their applications | |
| CN110448551A (en) | Dihydroqinghaosu is preparing the application in anti-angiogenic medicaments | |
| CA2968455A1 (en) | Antibacterial compounds having broad spectrum of activity | |
| CN110403933A (en) | Dihydroqinghaosu application in preparation of anti-tumor drugs | |
| US20140155345A1 (en) | Biotinylated compounds | |
| CN113874354B (en) | Pyridone derivative, preparation method thereof and application thereof in medicine | |
| CA3213573A1 (en) | Preparation method for bicyclic compound and application as antifungal agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191126 |
|
| RJ01 | Rejection of invention patent application after publication |